Abstract
Antimicrobial resistance to treatments for Clostridioides difficile infection (CDI) poses a significant threat to global health. C. difficile is widely thought to be susceptible to oral vancomycin, which is increasingly the mainstay of CDI treatment. However, clinical labs do not conduct C. difficile susceptibility testing, presenting a challenge to detecting the emergence and impact of resistance. In this systematic review, we describe gene determinants and associated clinical and laboratory mechanisms of vancomycin resistance in C. difficile, including drug-binding site alterations, efflux pumps, RNA polymerase mutations, and biofilm formation. Additional research is needed to further characterize these mechanisms and understand their clinical impact.
Funder
American College of Clinical Pharmacy
National Institute of Allergy and Infectious Diseases
Society of Infectious Diseases Pharmacists
Subject
Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Pharmacology, Toxicology and Pharmaceutics,Biochemistry,Microbiology
Reference65 articles.
1. Changes in Prevalence of Health Care–Associated Infections in U.S. Hospitals
2. Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection
3. Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 12.0https://www.eucast.org/clinical_breakpoints/
4. CLSI M100-ED31: 2021 Performance Standards for Antimicrobial Susceptibility Testing, 31st Editionhttp://em100.edaptivedocs.net/GetDoc.aspx?doc=CLSI%20M100%20ED31:2021&scope=user
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献